ITGB2 and neoplasm: We found that CD18/HPAF xenografts treated with RT and i.p injected Zol (16.4 μg/mouse, mouse equivalent dose calculated based on previous clinical trials) exhibited significantly greater RT response and reduced xenograft tumour weight and metastasis as compared to Zol or RT alone and control groups (Figures. 3c–e and S8b).